证券代码：300887 证券简称：谱尼测试 公告编号：2025-005 谱尼测试集团股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 谱尼测试集团股份有限公司（以下简称"公司"）于 2025 年 1 月 17 日召开 了第五届董事会第十七次会议及第五届监事会第十五次会议，审议通过了《关于 作废 2021 年限制性股票激励计划部分已授予尚未归属限制性股票的议案》，同 意对 2021 年限制性股票激励计划首次授予部分第一类激励对象第二个归属期和 第二类激励对象第一个归属期已届满但尚未归属的限制性股票进行作废处理，数 量为 1,615,353 股。现将有关事项说明如下： 一、激励计划简述 （一）标的股票来源 本激励计划涉及的标的股票来源为公司向激励对象定向发行公司 A 股普通 股。 （二）限制性股票的授予对象及数量 1、本激励计划首次授予第二类限制性股票的激励对象总人数共计 358 人， 为公司公告本激励计划时在公司（含全资子公司或控股子公司，下同）任职的董 事长、董事、董事会秘书以及董事会认为需要激励的其他人员。根据激励对象对 公司贡献度不同，将激励对 ...

证券代码：300887 证券简称：谱尼测试 公告编号：2024-079 谱尼测试集团股份有限公司 第五届董事会第十六次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 谱尼测试集团股份有限公司（以下简称"公司"）第五届董事会第十六次 会议于 2024 年 11 月 22 日下午在北京市海淀区中关村环保科技示范园锦带路 66 号院 1 号楼谱尼测试大厦 207 会议室以现场表决的方式召开。本次会议的通知已 于 2024 年 11 月 18 日以专人送达的方式发出。会议由董事长宋薇女士召集和主 持，会议应出席董事 6 人，实际出席董事 6 人，公司监事列席了会议。本次会议 的召集、召开符合《公司法》和《公司章程》的有关规定。 二、董事会会议审议情况 出席会议的董事对各项议案进行了认真审议并做出了如下决议： （一）审议通过《关于向工商银行申请综合授信额度的议案》 为满足公司日常经营与发展的资金需求，综合考虑公司资金安排，董事会同 意公司向中国工商银行股份有限公司北京昌平支行申请不超过等值人民币 10,000 万元的综合授信额度，授 ...

证券代码：300887 证券简称：谱尼测试 公告编号：2024-076 谱尼测试集团股份有限公司 关于全资子公司通过 GLP 检查并获得 《药物 GLP 认证证书》的公告 单次和重复给药毒性试验（啮齿类）；单次和重复给药毒性试验（非啮齿类， 不含灵长类）；遗传毒性试验（Ames、微核、染色体畸变）；局部毒性试验； 安全药理学试验；毒代动力学试验。 3、认证结论：根据《中华人民共和国药品管理法》及《药物非临床研究质 量管理规范认证管理办法》的有关规定，经审查，谱尼上海生物医药符合药物非 临床研究质量管理规范的要求。 4、有效期：至 2029 年 10 月 27 日 二、本次通过 GLP 检查对公司的影响 谱尼上海生物医药此次获得《药物 GLP 认证证书》，具备了药物非临床安 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，谱尼测试集团股份有限公司（以下简称"公司"）全资子公司谱尼 生物医药科技（上海）有限公司（以下简称"谱尼上海生物医药"）收到国家药 品监督管理局颁发的《药物 GLP 认证证书》。现将相关情况公告如下： 一、本次通过 GLP 检查及获得《药 ...

证券代码：300887 证券简称：谱尼测试 公告编号：2024-074 谱尼测试集团股份有限公司 内容详见同日刊登于中国证监会指定创业板信息披露网站巨潮资讯网 （http://www.cninfo.com.cn）的相关公告。 表决结果：3 票同意，0 票反对，0 票弃权，审议通过本项议案。 一、监事会会议召开情况 谱尼测试集团股份有限公司（以下简称"公司"）第五届监事会第十四次 会议于 2024 年 10 月 23 日下午在北京市海淀区中关村环保科技示范园锦带路 66 号院 1 号楼谱尼测试大厦 207 会议室以现场表决的方式召开，本次会议的通知已 于 2024 年 10 月 18 日以专人送达的方式发出。会议由监事会主席吴俊霞女士召 集和主持，会议应出席监事 3 人，实际出席监事 3 人。本次会议的召集、召开符 合《公司法》和《公司章程》的有关规定。 二、监事会会议审议情况 出席会议的监事对各项议案进行了认真审议并做出了如下决议： （一）审议通过《关于〈2024 年第三季度报告〉的议案》 经审核，监事会认为：董事会编制和审核公司《2024 年第三季度报告》符 合法律、行政法规和中国证监会的规定，报告内容真实 ...

Revenue and Profitability - Revenue for Q3 2024 was CNY 395,340,477.77, a decrease of 30.77% year-over-year[2] - Net profit attributable to shareholders was a loss of CNY 62,769,423.34, down 621.24% compared to the same period last year[2] - Operating profit for the year-to-date was a loss of CNY 236,967,567.47, a decline of 286.83% compared to the same period last year[6] - Total operating revenue for the current period is ¥1,123,414,813.30, a decrease of 36.2% compared to ¥1,758,239,802.93 in the previous period[15] - Net profit for the current period is -¥232,284,161.44, compared to a net profit of ¥106,862,369.46 in the previous period, indicating a significant loss[16] - Basic earnings per share for the current period is -0.4288, compared to 0.1931 in the previous period, indicating a decline in profitability[17] - The total comprehensive income for the current period is -¥232,280,901.65, compared to ¥106,856,136.00 in the previous period, indicating a substantial decline[17] Cash Flow and Financial Activities - The net cash flow from operating activities for the year-to-date was a negative CNY 116,167,781.29, representing a decline of 219.68% year-over-year[2] - Cash received from sales decreased by 35.56% to ¥1,153,939,674.76 compared to ¥1,790,621,509.56 in the same period last year[7] - Cash flow from operating activities shows a net outflow of -¥116,167,781.29, contrasting with a net inflow of ¥97,066,416.16 in the previous period[18] - Total cash inflow from financing activities increased by 31.74% to ¥216,808,967.28 compared to ¥164,568,545.61 in the previous year[7] - The net cash flow from financing activities was -19,153,361.63 CNY, an improvement compared to -177,652,644.69 CNY in the previous quarter[19] Assets and Liabilities - Total assets decreased by 8.77% from the end of the previous year, amounting to CNY 3,957,737,675.69[2] - The company's equity attributable to shareholders decreased by 7.55% to CNY 3,194,739,815.79 compared to the end of the previous year[2] - Total liabilities decreased from CNY 870,630,239.33 to CNY 751,418,088.27, reflecting a reduction of approximately 13.7%[14] - The total current assets decreased from CNY 2,307,439,472.52 to CNY 1,985,629,926.19, reflecting a decline of about 13.9%[12] - The total non-current assets decreased from CNY 2,030,617,028.66 to CNY 1,972,107,749.50, a decline of approximately 2.9%[13] Cash and Equivalents - Cash and cash equivalents decreased by 44.52% to CNY 343,846,858.64, primarily due to reduced sales collections[5] - Cash and cash equivalents dropped significantly from CNY 619,767,851.89 to CNY 343,846,858.64, a decrease of about 44.5%[12] - The ending balance of cash and cash equivalents was 339,540,695.93 CNY, down from 533,163,319.10 CNY in the previous quarter[19] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 22,848[8] - The largest shareholder, Song Wei, holds 44.83% of the shares, totaling 244,645,596[8] Other Financial Metrics - The company reported a total of CNY 4,667,724.76 in non-recurring gains and losses for the current period[3] - Interest income decreased by 56.64% to CNY 4,040,661.77, attributed to reduced funds and lower deposit rates[6] - The company reported a significant increase in other income, up 340.20% to ¥1,156,543.53, mainly from penalties and insurance claims[7] - The company’s tax expense was negative at -¥6,050,360.73, reflecting operational losses and the recognition of deferred tax assets[7] - The company reported a decrease in research and development expenses to ¥120,619,470.24, down from ¥142,106,527.87, reflecting a 15.1% reduction[15] Investment Activities - Cash outflow for purchasing fixed assets decreased by 67.41% to ¥149,292,374.03 from ¥458,083,893.97[7] - The cash paid for the acquisition of fixed assets, intangible assets, and other long-term assets was 149,292,374.03 CNY, significantly lower than 458,083,893.97 CNY in the previous quarter[19] Audit and Reporting - The third quarter report was not audited, indicating potential areas for further scrutiny in financial reporting[19]

证券代码：300887 证券简称：谱尼测试 公告编号：2024-073 谱尼测试集团股份有限公司 第五届董事会第十五次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 谱尼测试集团股份有限公司（以下简称"公司"）第五届董事会第十五次 会议于 2024 年 10 月 23 日下午在北京市海淀区中关村环保科技示范园锦带路 66 号院 1 号楼谱尼测试大厦 207 会议室以现场表决的方式召开。本次会议的通知已 于 2024 年 10 月 18 日以专人送达的方式发出。会议由董事长宋薇女士召集和主 持，会议应出席董事 6 人，实际出席董事 6 人，公司监事列席了会议。本次会议 的召集、召开符合《公司法》和《公司章程》的有关规定。 二、董事会会议审议情况 出席会议的董事对各项议案进行了认真审议并做出了如下决议： （一）审议通过《关于〈2024 年第三季度报告〉的议案》 经审议，董事会认为：公司《2024 年第三季度报告》符合法律、行政法规、 中国证券监督管理委员会和深圳证券交易所的相关规定，内容真实、准确、完整， 不存在任何虚假记载、误导性陈述或重大遗漏。 ...

证券代码：300887 证券简称：谱尼测试 公告编号：2024-072 谱尼测试集团股份有限公司 1、股东减持股份情况 | 大宗交易 | 2024/7/24 | 至 | - | - | - | | --- | --- | --- | --- | --- | --- | | | 2024/10/14 | | | | | | 合计 | | | | 624,893 | 0.11% | 2、本次减持前后持股变动情况： | 股东名称 | 股份性质 | 变动前持股情况 | | 变动后持股情况 | | | --- | --- | --- | --- | --- | --- | | | | 股份数 | 占总股 | 股份数 | 占总股 | | | | （股） | 本比例 | （股） | 本比例 | | 谱泰中瑞 | 合计持有股份 | 21,546,000 | 3.95% | 20,921,107 | 3.83% | | | 其中：无限售条件股份 | 21,546,000 | 3.95% | 20,921,107 | 3.83% | | | 有限售条件股份 | 0.00 | - | 0.00 | - | | 谱瑞恒祥 | 合计持 ...

证券代码：300887 证券简称：谱尼测试 谱尼测试集团股份有限公司投资者关系活动记录表 编号：2024-002 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |----------------|-------------------------------------|--------------------------|-------|-------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | □特定对象调研 | 分析师会议 | | | | | | | | | 投资者关系活动 | □媒体采访 □新闻发布会 | ☑ 业绩说明会 路演活动 | | | | | | | | | 类别 | 现场参观 | | | | | | | | | | | 其他（电话会议） | | | | | | | | | | 活动参与人员 | 详见附件 | | | | | | | | | | 时间 | 2024 年 8 月 29 日-9 月 | 20 日 | | | | | ...

华泰联合证券有限责任公司 关于谱尼测试集团股份有限公司 2024 年半年度持续督导跟踪报告 | 保荐人名称：华泰联合证券有限责任公司 | 被保荐公司简称：谱尼测试集团股份有限公司 | | --- | --- | | 保荐代表人姓名：刘晓宁 | 联系电话：010-56839300 | | 保荐代表人姓名：王禹 | 联系电话：010-56839300 | 一、保荐工作概述 | 项目 | 工作内容 | | --- | --- | | 1.公司信息披露审阅情况 | | | （1）是否及时审阅公司信息披露文件 | 是 | | （2）未及时审阅公司信息披露文件的次数 | 无 | | 2．督导公司建立健全并有效执行规章制度的情况 | | | （1）是否督导公司建立健全规章制度（包括 但不限于防止关联方占用公司资源的制度、 | | | | 是 | | 募集资金管理制度、内控制度、内部审计制 | | | 度、关联交易制度） | | | | 除"二、保荐人发现公司存在的问题及采取的 | | （2）公司是否有效执行相关规章制度 | 措施"之"1.信息披露"所述不规范情形外， | | | 公司有效执行相关规章制度 | | 3.募集资 ...

Investment Rating - The report maintains an "Accumulate" rating for the company [1] Core Views - The company is experiencing short-term pressure on performance due to strategic adjustments and a weak downstream market in biomedicine, with expectations for profit recovery in the future [2][3] - The company has shifted its focus towards enterprise clients, impacting new order acquisition, and is currently undergoing a strategic transformation [2] - The company is investing in new laboratory facilities across multiple regions to enhance its comprehensive testing capabilities [3] Financial Performance Summary - In the first half of 2024, the company achieved total revenue of 730 million yuan, a year-on-year decrease of 39%, and a net profit attributable to shareholders of -170 million yuan, a year-on-year decline of 284% [2] - The gross profit margin for the first half of 2024 was 28.8%, down 15.7 percentage points year-on-year, while the net profit margin was -23.6%, down 31.5 percentage points year-on-year [3] - The company has adjusted its earnings forecasts for 2024-2026 to 0.08 billion yuan (previously 3.0 billion), 1.7 billion yuan (previously 3.8 billion), and 2.7 billion yuan (previously 4.6 billion), respectively [3] Business Segment Performance - Revenue from the life sciences and environmental health segment was 500 million yuan, a decrease of 45% year-on-year, while revenue from the automotive and other consumer goods segment was 130 million yuan, an increase of 4% year-on-year [2] - The company is currently facing challenges in its traditional business client structure and is experiencing losses due to fixed costs from newly established laboratories [2][3] Market Data - The company's closing price is 6.46 yuan, with a market capitalization of approximately 3.53 billion yuan [4] - The price-to-earnings ratio (P/E) based on the latest diluted earnings per share is projected to be 433.85 for 2024 [3][12]